Articles tagged "Rejection"

2020 American Transplant Congress
Routine Human Renal Allograft Biopsies Analyzed for mRNA Content with a Novel Nanostring mRNA Human Organ Transplant (HOT) Panel
I. Rosales¹, R. Smith¹, E. Acheampong¹, T. Kawai¹, T. Tsuji², K. Hotta³, R. Colvin¹
¹Massachusetts General Hospital, Boston, MA, ²Sapporo City General Hospital, Sapporo, Japan, ³Hokkaido University Hospital, Sapporo, Japan
*Purpose: In 2019 a Banff Working Group and Nanostring Technologies developed a panel of 770 mRNA probes for assessment of human organ allografts, based on…
2020 American Transplant Congress
CD38 Antibody Daratumumab for the Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection
K. Doberer¹, J. Kläger², G. A. Gualdoni¹, K. Mayer¹, F. Eskandary¹, H. Agis³, T. Reiter¹, R. Reindl-Schwaighofer¹, M. Wahrmann¹, G. Cohen¹, H. Haslacher⁴, G. Bond¹, I. Simonitsch-Klupp⁵, I. Farkash⁶, P. Halloran⁷, G. A. Böhmig¹
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine I, Medical University of Vienna, Vienna, Austria, ⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁶Dept. of Pathology, University of Michigan, Ann Arbor, MI, ⁷Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Late antibody-mediated rejection (ABMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells (PC) and natural killer (NK) cells expressing…
2020 American Transplant Congress
Five Year Patient Important Outcomes of Treated Acute Rejections Diagnosed with Protocol and Clinical Biopsy after Pancreas Transplant Alone for Type 1 Diabetes
Y. C. Kudva, S. R. Rizvi, R. Kaur, B. H. Smith, S. Batthula, P. G. Dean, A. Kukla, W. K. Kremers, M. D. Stegall
Mayo Clinic, Rochester, MN
*Purpose: STUDY PURPOSE: Acute rejection (AR) after Pancreas Transplant alone (PTA) continues to be a significant morbidity. We compared the outcomes of PTA recipients treated…
2020 American Transplant Congress
Anti-T Lymphocyte Immunoglobulins versus Basiliximab in Highly Sensitized Kidney-Transplant Patients without Preformed DSAs: The Satir Study
N. Kamar¹, L. Couzi², L. Albano³, A. Durrbach⁴, V. Pernin⁵, L. Esposito¹, M. Lequintrec⁵, P. Merville², A. Del Bello¹
¹Toulouse University Hospital, Toulouse, France, ²Bordeaux University Hospital, Bordeaux, France, ³Nice University Hospital, Nice, France, ⁴Henri Mondor University Hospital, Paris, France, ⁵Montpellier University Hospital, Montpellier, France
*Purpose: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly…
2020 American Transplant Congress
Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant
T. J. ONeill IV, G. Jao, A. Kelkar, B. Pisani
Wake Forest Baptist Health System, Winston Salem, NC
*Purpose: The use of induction therapy after cardiac transplantation remains highly variable, not only in terms of which agent is used, but whether it is…
2020 American Transplant Congress
Inflammatory Cytokines Have a Different Effect from One HLA-II Subclass to Another on Human Endothelium
S. Beland, F. Bouchard-Boivin, A. Gama, O. Desy, S. A. De Serres
Universite Laval, Quebec, QC, Canada
*Purpose: Development of de novo donor-specific antibodies (DSAs) is associated with antibody-mediated rejection and allograft failure. More particularly, HLA-II DSAs, especially those against DQ are…
2020 American Transplant Congress
Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
Y. Kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Regulation, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Owing to limited organ availability, ABO-incompatible living kidney transplantation (ABO-ILKT) has been used extensively. Various forms of preconditioning therapies have been used alone or…
2020 American Transplant Congress
B Cell Derived IL-1β and IL-6 Drive Homeostatic T Cell Recovery Following Lymphoablation
S. Hasgur, R. Fan, A. Valujskikh
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: T cell reconstitution after lymphoablation in allograft recipients may lead to acute rejection and poor graft outcome. Using a mouse model of heart transplantation…
2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…
2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…